HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.04.007v1 j.jacc.2007.04.007v2 49/21/2139    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ben-Yehuda, O. Search for Related Content PubMed Articles by Ben-Yehuda, O.

EXPEDITED REVIEW: COMMENTARY

High-Sensitivity C-Reactive Protein in Every Chart?

The Use of Biomarkers in Individual Patients

Department of Medicine, University of California, San Diego Medical Center, San Diego, California

Manuscript received March 6, 2007; revised manuscript received March 20, 2007, accepted March 28, 2007.

^_* Reprint requests and correspondence: Dr. Ori Ben-Yehuda, Department of Medicine, UCSD Medical Center, 200 West Arbor Drive, San Diego, California 92103. (Email: obyehuda{at}acc.org).

The use of high-sensitivity C-reactive protein (hsCRP) for risk stratification for cardiovascular disease is supported by epidemiologic evidence but remains controversial. The metabolic milieu in which hsCRP is likely to be elevated, namely abdominal obesity and insulin resistance, provides a framework for the understanding of the role of hsCRP as well its limitations. This commentary provides a critical assessment of the data in support of the use of hsCRP in clinical practice.